TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
Background. We investigated the efficacy of TILs and anti-PD1 combination therapy in patients with metastatic cervical cancer with low MSI expression and PDL1-negative. Methods. A total of 80 patients were put on TILs and anti-PD1 combination therapy, and the progression-free survival time (PFS) and...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2020/8345235 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546985804038144 |
|---|---|
| author | Huanhuan Yin Wei Guo Xiangling Sun Ruili Li Cuihua Feng Yujie Tan |
| author_facet | Huanhuan Yin Wei Guo Xiangling Sun Ruili Li Cuihua Feng Yujie Tan |
| author_sort | Huanhuan Yin |
| collection | DOAJ |
| description | Background. We investigated the efficacy of TILs and anti-PD1 combination therapy in patients with metastatic cervical cancer with low MSI expression and PDL1-negative. Methods. A total of 80 patients were put on TILs and anti-PD1 combination therapy, and the progression-free survival time (PFS) and overall survival time (OS) were assessed by Kaplan–Meier analysis. Univariate and multivariate analyses were performed to identify factors that could predict the prognosis of metastatic cervical cancer in the previously described patients. Results. The objective response rate was 25%, whereas the mPFS and mOS were 6.1 and 11.3 months, respectively. The therapeutic efficacy was influenced by the characteristics of TILs, infection with HPV, and development of fever just after the therapy. Conclusion. Overall, our results show that the combination therapy of TILs and anti-PD1 significantly improves the prognosis of metastatic cervical cancer. |
| format | Article |
| id | doaj-art-fa014c60caad4d54991022016b820fd7 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-fa014c60caad4d54991022016b820fd72025-02-03T06:46:35ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/83452358345235TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical CancerHuanhuan Yin0Wei Guo1Xiangling Sun2Ruili Li3Cuihua Feng4Yujie Tan5Department of Obstetrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, ChinaDepartment of Obstetrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, ChinaDepartment of Obstetrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, ChinaDepartment of Obstetrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, ChinaDepartment of Obstetrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, ChinaDepartment of Obstetrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, ChinaBackground. We investigated the efficacy of TILs and anti-PD1 combination therapy in patients with metastatic cervical cancer with low MSI expression and PDL1-negative. Methods. A total of 80 patients were put on TILs and anti-PD1 combination therapy, and the progression-free survival time (PFS) and overall survival time (OS) were assessed by Kaplan–Meier analysis. Univariate and multivariate analyses were performed to identify factors that could predict the prognosis of metastatic cervical cancer in the previously described patients. Results. The objective response rate was 25%, whereas the mPFS and mOS were 6.1 and 11.3 months, respectively. The therapeutic efficacy was influenced by the characteristics of TILs, infection with HPV, and development of fever just after the therapy. Conclusion. Overall, our results show that the combination therapy of TILs and anti-PD1 significantly improves the prognosis of metastatic cervical cancer.http://dx.doi.org/10.1155/2020/8345235 |
| spellingShingle | Huanhuan Yin Wei Guo Xiangling Sun Ruili Li Cuihua Feng Yujie Tan TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer Journal of Immunology Research |
| title | TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer |
| title_full | TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer |
| title_fullStr | TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer |
| title_full_unstemmed | TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer |
| title_short | TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer |
| title_sort | tils and anti pd1 therapy an alternative combination therapy for pdl1 negative metastatic cervical cancer |
| url | http://dx.doi.org/10.1155/2020/8345235 |
| work_keys_str_mv | AT huanhuanyin tilsandantipd1therapyanalternativecombinationtherapyforpdl1negativemetastaticcervicalcancer AT weiguo tilsandantipd1therapyanalternativecombinationtherapyforpdl1negativemetastaticcervicalcancer AT xianglingsun tilsandantipd1therapyanalternativecombinationtherapyforpdl1negativemetastaticcervicalcancer AT ruilili tilsandantipd1therapyanalternativecombinationtherapyforpdl1negativemetastaticcervicalcancer AT cuihuafeng tilsandantipd1therapyanalternativecombinationtherapyforpdl1negativemetastaticcervicalcancer AT yujietan tilsandantipd1therapyanalternativecombinationtherapyforpdl1negativemetastaticcervicalcancer |